Tags:

BioMarin Pharmaceutical Inc.


A securities class action has been filed against BioMarin Pharmaceutical Inc. (BMRN) on behalf of all those who purchased or acquired BioMarin Pharmaceutical securities between January 13, 2020 through September 3, 2021.  This case has been filed in the USDC – N. CA.

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) BMN 307 was less safe than BioMarin had led investors to believe; (ii) BMN 307’s safety profile made it likely that the FDA would place a clinical hold on the Phearless Phase 1/2 study; (iii) accordingly, the Company had overstated BMN 307’s clinical and commercial prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Tags:

Securities